首页 > 最新文献

Gastroenterologia y hepatologia最新文献

英文 中文
Thromboembolic phenomena in inflammatory bowel disease and risk with JAK inhibitor treatments. 炎症性肠病中的血栓栓塞现象及 JAK 治疗的风险。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-09-19 DOI: 10.1016/j.gastrohep.2024.502257
José Luis Rueda García, José Manuel Benitez, Iria Baston Rey, Margalida Calafat Sard, Cristina Suárez Ferrer
{"title":"Thromboembolic phenomena in inflammatory bowel disease and risk with JAK inhibitor treatments.","authors":"José Luis Rueda García, José Manuel Benitez, Iria Baston Rey, Margalida Calafat Sard, Cristina Suárez Ferrer","doi":"10.1016/j.gastrohep.2024.502257","DOIUrl":"10.1016/j.gastrohep.2024.502257","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502257"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of severe hypertriglyceridemia through therapeutic plasma exchange in patients with acute pancreatitis or at risk of developing it. 通过治疗性血浆置换,治疗急性胰腺炎患者或有患急性胰腺炎风险的患者的严重高甘油三酯血症。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-07-09 DOI: 10.1016/j.gastrohep.2024.502229
Eva Marín-Serrano, Ana Kerguelen Fuentes, Rubén Fernández-Martos, José Mostaza Prieto, Aurora Viejo Llorente, Ana Barbado Cano, Pedro Luis Martínez Hernández, María Dolores Martín-Arranz

Introduction and objectives: TPE drastically reduces serum triglyceride (sTG), but its role in the treatment of hypertriglyceridemia-induced acute pancreatitis (HTG-AP) or at risk of developing it, is not well established. The objectives were to assess the effectiveness and safety of TPE in the treatment of severe HTG (sHTG), as well as to evaluate the severity of HTG-AP treated with TPE.

Materials and methods: Observational-retrospective-single-center study, in which a descriptive analysis of sHTG treated with TPE was conducted, with the aim of treating HTG-AP or preventing its recurrence. TPE was performed if sTG≥ 1000 mg/dL after 24 hours of admission.

Results: 42 TPE were performed to treat 35 sHTG in 23 patients: 29 HTG-AP, and 6 sHTG with previous HTG-AP. Among the patients, 37% (13/55) were women, with 37 ± 14 years-old, 74.3% had normal BMI (25/35), 34% (12/35) were drinking > 40 g/alcohol/day and 54% (19/35) were diabetics. TPE significantly reduced the baseline sTG (4425 ± 2782 mg/dL vs. 709 ± 353 mg/dL, p < 0.001) in a single session, achieving a mean percentage reduction of 79 ± 13%; 20% (7/35) of sHTG cases required two TPE sessions to reduce sTG to < 1000 mg/dL. Adverse effects were reported in 4/42 TPE sessions (9,5%). sHTG-AP was observed in 3% of cases (1/29), and there were no deaths. sTG at 24 hours of admission showed no relation with the severity of APs.

Conclusion: The treatment of sHTG with TPE, with the aim of treating HTG-AP or preventing its recurrence, reduces sTG quickly and safety.

引言和目的:TPE可显著降低血清甘油三酯(sTG),但其在治疗高甘油三酯血症诱发的急性胰腺炎(HTG-AP)或有发生急性胰腺炎风险的患者中的作用尚未得到充分证实。研究目的是评估 TPE 治疗重度 HTG(sHTG)的有效性和安全性,并评估使用 TPE 治疗 HTG-AP 的严重程度:观察性-回顾性-单中心研究,对接受 TPE 治疗的 sHTG 进行描述性分析,目的是治疗 HTG-AP 或防止其复发。如果入院 24 小时后 sTG≥ 1000 mg/dL,则进行 TPE:结果:共进行了 42 次 TPE,治疗了 23 名患者中的 35 例 sHTG:结果:对 23 名患者中的 35 例高血压患者进行了 42 次 TPE 治疗,其中 29 例为 HTG-AP,6 例为既往接受过 HTG-AP 的高血压患者。患者中,37%(13/55)为女性,年龄为 37±14 岁,74.3%(25/35)体重指数正常,34%(12/35)饮酒量大于 40 克/天,54%(19/35)为糖尿病患者。TPE 明显降低了基线 sTG(4425±2782 mg/dL vs. 709±353 mg/dL, p结论:用 TPE 治疗 sHTG,旨在治疗 HTG-AP 或防止其复发,可快速、安全地降低 sTG。
{"title":"Treatment of severe hypertriglyceridemia through therapeutic plasma exchange in patients with acute pancreatitis or at risk of developing it.","authors":"Eva Marín-Serrano, Ana Kerguelen Fuentes, Rubén Fernández-Martos, José Mostaza Prieto, Aurora Viejo Llorente, Ana Barbado Cano, Pedro Luis Martínez Hernández, María Dolores Martín-Arranz","doi":"10.1016/j.gastrohep.2024.502229","DOIUrl":"10.1016/j.gastrohep.2024.502229","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>TPE drastically reduces serum triglyceride (sTG), but its role in the treatment of hypertriglyceridemia-induced acute pancreatitis (HTG-AP) or at risk of developing it, is not well established. The objectives were to assess the effectiveness and safety of TPE in the treatment of severe HTG (sHTG), as well as to evaluate the severity of HTG-AP treated with TPE.</p><p><strong>Materials and methods: </strong>Observational-retrospective-single-center study, in which a descriptive analysis of sHTG treated with TPE was conducted, with the aim of treating HTG-AP or preventing its recurrence. TPE was performed if sTG≥ 1000 mg/dL after 24 hours of admission.</p><p><strong>Results: </strong>42 TPE were performed to treat 35 sHTG in 23 patients: 29 HTG-AP, and 6 sHTG with previous HTG-AP. Among the patients, 37% (13/55) were women, with 37 ± 14 years-old, 74.3% had normal BMI (25/35), 34% (12/35) were drinking > 40 g/alcohol/day and 54% (19/35) were diabetics. TPE significantly reduced the baseline sTG (4425 ± 2782 mg/dL vs. 709 ± 353 mg/dL, p < 0.001) in a single session, achieving a mean percentage reduction of 79 ± 13%; 20% (7/35) of sHTG cases required two TPE sessions to reduce sTG to < 1000 mg/dL. Adverse effects were reported in 4/42 TPE sessions (9,5%). sHTG-AP was observed in 3% of cases (1/29), and there were no deaths. sTG at 24 hours of admission showed no relation with the severity of APs.</p><p><strong>Conclusion: </strong>The treatment of sHTG with TPE, with the aim of treating HTG-AP or preventing its recurrence, reduces sTG quickly and safety.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502229"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141590167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastric antral ectasia and diaphragmatic hernia: A rare cause of iron deficiency anemia. 胃前庭异位症和膈疝:缺铁性贫血的罕见病因。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-05-11 DOI: 10.1016/j.gastrohep.2024.502209
Ana Lancho Muñoz, Patricia Abellán Alfocea, Eduardo Redondo Cerezo
{"title":"Gastric antral ectasia and diaphragmatic hernia: A rare cause of iron deficiency anemia.","authors":"Ana Lancho Muñoz, Patricia Abellán Alfocea, Eduardo Redondo Cerezo","doi":"10.1016/j.gastrohep.2024.502209","DOIUrl":"10.1016/j.gastrohep.2024.502209","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502209"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heterotaxia syndrome: when almost nothing is as it should be. 异位综合征:当几乎所有事情都不尽如人意时。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-07-17 DOI: 10.1016/j.gastrohep.2024.502233
Luisa Adán-Merino, Francisco Garrido Gallego, Rodrigo Pastorín-Salis, Ángel Ponferrada-Díaz
{"title":"Heterotaxia syndrome: when almost nothing is as it should be.","authors":"Luisa Adán-Merino, Francisco Garrido Gallego, Rodrigo Pastorín-Salis, Ángel Ponferrada-Díaz","doi":"10.1016/j.gastrohep.2024.502233","DOIUrl":"10.1016/j.gastrohep.2024.502233","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502233"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141727052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased arterial stiffness in Crohn's disease: Prevalence, associated factors and impact of anti-TNF therapy. 克罗恩病患者动脉僵化加剧:发病率、相关因素和抗肿瘤坏死因子疗法的影响。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-09-11 DOI: 10.1016/j.gastrohep.2024.502252
Mahrez Fissah, Adel Rechach, Meriem Charifi, Farouk Menzou, Said Taharboucht, Messaouda Djouhri, Leila Talbi, Nadia Touati, Lamine Atif, Mehdi Rabhia, Ahcene Chibane

Introduction: Recent studies have demonstrated the growing interest in cardiovascular risk in Crohn's disease (CD), the aim of our work is to highlight the need for research into the frequency of arterial stiffness (AS) and its link with certain associated factors, particularly those related to inflammation.

Materials and methods: This was a cross-sectional observational study involving 118 patients with CD. Pulse wave velocity (PWV) measured by applanation tonometry was the criterion for calculating AS, the study also investigated the association of AS especially the indicators of inflammation, as well as the impact of anti-TNF alpha therapy on AS.

Results: The prevalence of AS, after adjustment for age and blood pressure level reached more than a quarter of patients compared to the cardiovascular risk which was low. The factors that were strongly associated with AS were age, systolic and diastolic blood pressure. Two parameters related to inflammation emerged as having a highly significant link after multivariate analysis: recurrence in the last year and length of disease with a p=0.008, and an OR of 5 and 9 successively. Patients treated with anti-TNF alpha had a significant reduction in PWV.

Conclusion: The prevalence of AS reached more than a quarter of patients with CD, the duration and recurrence rate of CD appear to be factors linked to inflammation. Treatment with anti-TNF alpha seems to slow down PWV in these patients.

导言:最近的研究表明,人们越来越关注克罗恩病(CD)的心血管风险,我们的工作旨在强调研究动脉僵化(AS)频率及其与某些相关因素(尤其是与炎症有关的因素)之间联系的必要性:这是一项横断面观察研究,涉及 118 名 CD 患者。研究还调查了动脉僵化与炎症指标的关联,以及抗 TNF α 治疗对动脉僵化的影响:结果:在对年龄和血压水平进行调整后,超过四分之一的患者患有强直性脊柱炎,而心血管风险较低。与强直性脊柱炎密切相关的因素是年龄、收缩压和舒张压。经过多变量分析,有两个与炎症相关的参数与强直性脊柱炎有非常显著的联系:去年的复发率和病程,P=0.008,OR 值分别为 5 和 9。接受抗 TNF α 治疗的患者脉搏波速度明显降低。结论 :在CD患者中,强直性脊柱炎的发病率超过四分之一,CD的病程和复发率似乎与炎症有关。抗肿瘤坏死因子α治疗似乎能减缓这些患者的脉搏波速度。
{"title":"Increased arterial stiffness in Crohn's disease: Prevalence, associated factors and impact of anti-TNF therapy.","authors":"Mahrez Fissah, Adel Rechach, Meriem Charifi, Farouk Menzou, Said Taharboucht, Messaouda Djouhri, Leila Talbi, Nadia Touati, Lamine Atif, Mehdi Rabhia, Ahcene Chibane","doi":"10.1016/j.gastrohep.2024.502252","DOIUrl":"10.1016/j.gastrohep.2024.502252","url":null,"abstract":"<p><strong>Introduction: </strong>Recent studies have demonstrated the growing interest in cardiovascular risk in Crohn's disease (CD), the aim of our work is to highlight the need for research into the frequency of arterial stiffness (AS) and its link with certain associated factors, particularly those related to inflammation.</p><p><strong>Materials and methods: </strong>This was a cross-sectional observational study involving 118 patients with CD. Pulse wave velocity (PWV) measured by applanation tonometry was the criterion for calculating AS, the study also investigated the association of AS especially the indicators of inflammation, as well as the impact of anti-TNF alpha therapy on AS.</p><p><strong>Results: </strong>The prevalence of AS, after adjustment for age and blood pressure level reached more than a quarter of patients compared to the cardiovascular risk which was low. The factors that were strongly associated with AS were age, systolic and diastolic blood pressure. Two parameters related to inflammation emerged as having a highly significant link after multivariate analysis: recurrence in the last year and length of disease with a p=0.008, and an OR of 5 and 9 successively. Patients treated with anti-TNF alpha had a significant reduction in PWV.</p><p><strong>Conclusion: </strong>The prevalence of AS reached more than a quarter of patients with CD, the duration and recurrence rate of CD appear to be factors linked to inflammation. Treatment with anti-TNF alpha seems to slow down PWV in these patients.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502252"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnés (Spain). 人工智能辅助识别和检索庞特韦德拉和奥萨尔内斯卫生区(西班牙)失去随访的慢性丙型肝炎患者。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-06-29 DOI: 10.1016/j.gastrohep.2024.502226
Pablo Parada Vázquez, Santiago Pérez-Cachafeiro, Belén Castiñeira Domínguez, Juan Manuel González-Pérez, José Manuel Mera Calviño, Raquel Souto-Rodríguez, Yolanda Falagán Cachafeiro, Indhira Pérez-Medrano, Nuria Vázquez-Temprano, Matilde Trigo, Alba Carrodeguas, José Luis González-Sánchez, Carmen Durán-Parrondo, Juan Turnes

Objective: Direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection offer an opportunity to eliminate the disease. This study aimed to identify and relink to care HCV patients previously lost to medical follow-up in the health area of Pontevedra and O Salnés (Spain) using an artificial intelligence-assisted system.

Patients and methods: Active retrospective search of previously diagnosed HCV cases recorded in the Galician Health Service proprietary health information exchange database using the Herramientas para la EXplotación de la INformación (HEXIN) application.

Results and conclusions: Out of 99 lost patients identified, 64 (64.6%) were retrieved. Of these, 62 (96.88%) initiated DAA treatment and 54 patients (87.1%) achieved a sustained virological response. Mean time from HCV diagnosis was over 10 years. Main reasons for loss to follow-up were fear of possible adverse effects of treatment (30%) and mobility impediments (21%). Among the retrieved patients, almost one in three presented advanced liver fibrosis (F3) or cirrhosis (F4) at evaluation. In sum, HCV patients lost to follow-up can be retrieved by screening past laboratory records. This strategy promotes the achievement of HCV elimination goals.

目的:治疗丙型肝炎病毒(HCV)感染的直接作用抗病毒药物(DAAs)为消除该疾病提供了机会。本研究旨在利用人工智能辅助系统,在庞特韦德拉和奥萨尔内斯(西班牙)卫生保健区发现之前失去医疗随访的丙型肝炎病毒(HCV)患者,并将其重新链接到医疗机构:使用 Herramientas para la EXplotación de la INformación (HEXIN) 应用程序对加利西亚卫生服务专有卫生信息交换数据库中记录的先前诊断的 HCV 病例进行主动回顾性搜索:在已确认的 99 名失访患者中,有 64 人(64.6%)被找回。其中,62 名患者(96.88%)接受了 DAA 治疗,54 名患者(87.1%)获得了持续病毒学应答。从确诊为丙型肝炎病毒到现在的平均时间超过 10 年。失去随访的主要原因是担心治疗可能产生不良反应(30%)和行动不便(21%)。在失访患者中,几乎三分之一的患者在评估时出现了晚期肝纤维化(F3)或肝硬化(F4)。总之,通过筛查过去的实验室记录,可以找回失去随访的 HCV 患者。这一策略有助于实现消除 HCV 的目标。
{"title":"Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnés (Spain).","authors":"Pablo Parada Vázquez, Santiago Pérez-Cachafeiro, Belén Castiñeira Domínguez, Juan Manuel González-Pérez, José Manuel Mera Calviño, Raquel Souto-Rodríguez, Yolanda Falagán Cachafeiro, Indhira Pérez-Medrano, Nuria Vázquez-Temprano, Matilde Trigo, Alba Carrodeguas, José Luis González-Sánchez, Carmen Durán-Parrondo, Juan Turnes","doi":"10.1016/j.gastrohep.2024.502226","DOIUrl":"10.1016/j.gastrohep.2024.502226","url":null,"abstract":"<p><strong>Objective: </strong>Direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection offer an opportunity to eliminate the disease. This study aimed to identify and relink to care HCV patients previously lost to medical follow-up in the health area of Pontevedra and O Salnés (Spain) using an artificial intelligence-assisted system.</p><p><strong>Patients and methods: </strong>Active retrospective search of previously diagnosed HCV cases recorded in the Galician Health Service proprietary health information exchange database using the Herramientas para la EXplotación de la INformación (HEXIN) application.</p><p><strong>Results and conclusions: </strong>Out of 99 lost patients identified, 64 (64.6%) were retrieved. Of these, 62 (96.88%) initiated DAA treatment and 54 patients (87.1%) achieved a sustained virological response. Mean time from HCV diagnosis was over 10 years. Main reasons for loss to follow-up were fear of possible adverse effects of treatment (30%) and mobility impediments (21%). Among the retrieved patients, almost one in three presented advanced liver fibrosis (F3) or cirrhosis (F4) at evaluation. In sum, HCV patients lost to follow-up can be retrieved by screening past laboratory records. This strategy promotes the achievement of HCV elimination goals.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502226"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd).
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-09-30 DOI: 10.1016/j.gastrohep.2024.502208
Agustín Albillos, Rafael Bañares, Virginia Hernández-Gea

Portal hypertension is a hemodynamic abnormality that complicates the course of cirrhosis, as well as other diseases that affect the portal venous circulation. The development of portal hypertension compromises prognosis, especially when it rises above a certain threshold known as clinically significant portal hypertension (CSPH). In the consensus conference on Portal Hypertension promoted by the Spanish Association for the Study of the Liver and the Hepatic and Digestive diseases area of the Biomedical Research Networking Center (CIBERehd), different aspects of the diagnosis and treatment of portal hypertension caused by cirrhosis or other diseases were discussed. The outcome of this discussion was a set of recommendations that achieved varying degrees of consensus among panelists and are reflected in this consensus document. The six areas under discussion were: the relevance of CSPH and the non-invasive methods used for its diagnosis and that of cirrhosis, the prevention of the first episode of decompensation and its recurrence, the treatment of acute variceal bleeding and other complications of portal hypertension, the indications for the use of TIPS, and finally, the diagnosis and treatment of liver vascular diseases.

{"title":"Portal hypertension: recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd).","authors":"Agustín Albillos, Rafael Bañares, Virginia Hernández-Gea","doi":"10.1016/j.gastrohep.2024.502208","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2024.502208","url":null,"abstract":"<p><p>Portal hypertension is a hemodynamic abnormality that complicates the course of cirrhosis, as well as other diseases that affect the portal venous circulation. The development of portal hypertension compromises prognosis, especially when it rises above a certain threshold known as clinically significant portal hypertension (CSPH). In the consensus conference on Portal Hypertension promoted by the Spanish Association for the Study of the Liver and the Hepatic and Digestive diseases area of the Biomedical Research Networking Center (CIBERehd), different aspects of the diagnosis and treatment of portal hypertension caused by cirrhosis or other diseases were discussed. The outcome of this discussion was a set of recommendations that achieved varying degrees of consensus among panelists and are reflected in this consensus document. The six areas under discussion were: the relevance of CSPH and the non-invasive methods used for its diagnosis and that of cirrhosis, the prevention of the first episode of decompensation and its recurrence, the treatment of acute variceal bleeding and other complications of portal hypertension, the indications for the use of TIPS, and finally, the diagnosis and treatment of liver vascular diseases.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":"48 1","pages":"502208"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adaptation and validation of an abbreviated version of the SIPAT integrated psychosocial risk scale in patients with liver cirrhosis candidates for liver transplantation (SIPAT-11). 肝硬化肝移植候选患者社会心理风险综合量表缩略版(SIPAT-11)的改编与验证。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-06-19 DOI: 10.1016/j.gastrohep.2024.502220
Natalia García Morales, Sagrario Gutiérrez Morato, Carmen Castillo Cejas, Margarita Fernández de la Varga, Martín Menéndez Rodríguez, Victoria Aguilera, Salvador Benlloch, Luis Menéndez Rodríguez, Teresa Seoane Pillado, Joaquín Cubiella

Introduction: Patients with liver cirrhosis who are candidates for liver transplantation must be evaluated both clinically and socially in order to obtain the optimal outcomes and avoid futile therapeutic measures. For the evaluation of the social aspects in these patients, no validated scale in Spanish is available. The SIPAT (Stanford Integrated Psychosocial Assessment for Transplantation) scale is an instrument that measures the social, family and psychological aspects in candidates for solid organ transplantation. The objective of this study is to adapt and validate an abbreviated version of the SIPAT scale in Spanish for patients with liver cirrhosis.

Material and methods: Prospective observational study carried out in the Hepatology Unit of the La Fe Unversity Hospital in Valencia, by questionnaire validation methodology. To analyze the reliability of the questionnaire, the internal consistency of all variables was calculated, for variability an exploratory factor analysis, and for stability the test-retest test was carried out.

Results: 96 patients who were admitted for decompensated cirrhosis to the Hepatology Unit of the La Fe Hospital in Valencia between November 1, 2017 and January 31, 2017 were selected. 84% were men, the mean age was 60.01 (SD 10.12) years. In 73.2% of those admitted, the etiology of cirrhosis was alcoholic. 14.4% had a Child's stage A, 57.7% B and 27.8% C. The internal consistency of all variables reached a Cronbach's Alpha of 0.766. In the exploratory factor analysis, 6 dimensions of the questionnaire were identified that explain 84.27% of the total variability. To see the stability of the instrument, the measurement was repeated at 2 and 6 months of follow-up, obtaining in the test-retest a kappa agreement of 0.612 and 0.565 respectively.

Conclusion: The SIPAT-11 questionnaire has good psychometric characteristics in cirrhotic patients who are candidates for liver transplantation. It is easy to complete and can be administered by professionals who are not specialists in the area of Mental Health.

导言:肝硬化患者是肝脏移植的候选者,必须对其进行临床和社会评估,以获得最佳治疗效果,避免采取徒劳无益的治疗措施。对于这些患者的社会方面评估,目前还没有西班牙文的有效量表。SIPAT(斯坦福移植综合社会心理评估)量表是一种测量实体器官移植候选者的社会、家庭和心理方面的工具。本研究的目的是改编并验证适用于肝硬化患者的西班牙语 SIPAT 量表缩写版:在巴伦西亚拉费大学医院肝病科开展的前瞻性观察研究,采用问卷验证法。为分析问卷的可靠性,计算了所有变量的内部一致性,对变异性进行了探索性因子分析,对稳定性进行了重复测试:选取了2017年11月1日至2017年1月31日期间巴伦西亚拉费医院肝病科收治的96名失代偿期肝硬化患者。84%为男性,平均年龄为60.01岁(标清10.12岁)。73.2%的入院患者的肝硬化病因是酒精性肝硬化。所有变量的内部一致性达到 Cronbach's Alpha 0.766。在探索性因子分析中,确定了问卷的 6 个维度,它们解释了 84.27% 的总变异性。为了解该工具的稳定性,在 2 个月和 6 个月的随访中重复进行了测量,在重复测试中获得的 kappa 一致度分别为 0.612 和 0.565:SIPAT-11问卷对肝移植候选者中的肝硬化患者具有良好的心理测量特性。该问卷易于填写,可由非心理健康领域专家的专业人员进行管理。
{"title":"Adaptation and validation of an abbreviated version of the SIPAT integrated psychosocial risk scale in patients with liver cirrhosis candidates for liver transplantation (SIPAT-11).","authors":"Natalia García Morales, Sagrario Gutiérrez Morato, Carmen Castillo Cejas, Margarita Fernández de la Varga, Martín Menéndez Rodríguez, Victoria Aguilera, Salvador Benlloch, Luis Menéndez Rodríguez, Teresa Seoane Pillado, Joaquín Cubiella","doi":"10.1016/j.gastrohep.2024.502220","DOIUrl":"10.1016/j.gastrohep.2024.502220","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with liver cirrhosis who are candidates for liver transplantation must be evaluated both clinically and socially in order to obtain the optimal outcomes and avoid futile therapeutic measures. For the evaluation of the social aspects in these patients, no validated scale in Spanish is available. The SIPAT (Stanford Integrated Psychosocial Assessment for Transplantation) scale is an instrument that measures the social, family and psychological aspects in candidates for solid organ transplantation. The objective of this study is to adapt and validate an abbreviated version of the SIPAT scale in Spanish for patients with liver cirrhosis.</p><p><strong>Material and methods: </strong>Prospective observational study carried out in the Hepatology Unit of the La Fe Unversity Hospital in Valencia, by questionnaire validation methodology. To analyze the reliability of the questionnaire, the internal consistency of all variables was calculated, for variability an exploratory factor analysis, and for stability the test-retest test was carried out.</p><p><strong>Results: </strong>96 patients who were admitted for decompensated cirrhosis to the Hepatology Unit of the La Fe Hospital in Valencia between November 1, 2017 and January 31, 2017 were selected. 84% were men, the mean age was 60.01 (SD 10.12) years. In 73.2% of those admitted, the etiology of cirrhosis was alcoholic. 14.4% had a Child's stage A, 57.7% B and 27.8% C. The internal consistency of all variables reached a Cronbach's Alpha of 0.766. In the exploratory factor analysis, 6 dimensions of the questionnaire were identified that explain 84.27% of the total variability. To see the stability of the instrument, the measurement was repeated at 2 and 6 months of follow-up, obtaining in the test-retest a kappa agreement of 0.612 and 0.565 respectively.</p><p><strong>Conclusion: </strong>The SIPAT-11 questionnaire has good psychometric characteristics in cirrhotic patients who are candidates for liver transplantation. It is easy to complete and can be administered by professionals who are not specialists in the area of Mental Health.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502220"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cerebral thrombosis as a manifestation of poor control in inflammatory bowel disease. 脑血栓是炎症性肠病控制不佳的一种表现。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-09-28 DOI: 10.1016/j.gastrohep.2024.502256
Marta Fernández Carrasco, Ana Delgado Maroto, Álvaro Hernández Martínez
{"title":"Cerebral thrombosis as a manifestation of poor control in inflammatory bowel disease.","authors":"Marta Fernández Carrasco, Ana Delgado Maroto, Álvaro Hernández Martínez","doi":"10.1016/j.gastrohep.2024.502256","DOIUrl":"10.1016/j.gastrohep.2024.502256","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502256"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combined biologic treatment in patient with chronic spontaneous urticaria and Crohn's disease. 慢性自发性荨麻疹和克罗恩病患者的联合生物治疗。
IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-01 Epub Date: 2024-05-28 DOI: 10.1016/j.gastrohep.2024.502213
Alejandro García Martínez, María Del Pilar Lobato de la Sierra, Teresa Castro Aguilar-Tablada
{"title":"Combined biologic treatment in patient with chronic spontaneous urticaria and Crohn's disease.","authors":"Alejandro García Martínez, María Del Pilar Lobato de la Sierra, Teresa Castro Aguilar-Tablada","doi":"10.1016/j.gastrohep.2024.502213","DOIUrl":"10.1016/j.gastrohep.2024.502213","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502213"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Gastroenterologia y hepatologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1